IN2014KN01682A - - Google Patents

Info

Publication number
IN2014KN01682A
IN2014KN01682A IN1682KON2014A IN2014KN01682A IN 2014KN01682 A IN2014KN01682 A IN 2014KN01682A IN 1682KON2014 A IN1682KON2014 A IN 1682KON2014A IN 2014KN01682 A IN2014KN01682 A IN 2014KN01682A
Authority
IN
India
Prior art keywords
human
receptor antagonist
mammalian
expression
itr
Prior art date
Application number
Inventor
Brendan Lee
Kilian Guse
Zhechao Ruan
Original Assignee
Baylor College Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baylor College Medicine filed Critical Baylor College Medicine
Publication of IN2014KN01682A publication Critical patent/IN2014KN01682A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/545—IL-1
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10071—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10371—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/24—Vectors characterised by the absence of particular element, e.g. selectable marker, viral origin of replication

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The invention relates to an adenoviral based biological delivery and expression system for use in the treatment or prevention of osteoathritis in human or mammalian joints by long term inducible gene expression of human or mammalian interleukin 1 receptor antagonist (II 1 Ra) in synovial cells comprising a helper dependent adenoviral vector containing a nucleic acid sequence encoding for human or mammalian interleukin 1 receptor antagonist (II 1 Ra) left and right inverted terminal repeats (L ITR and R ITR) the adenoviral packaging signal and non viral non coding stuffer nucleic acid sequences wherein the expression of the human or mammalian interleukin 1 receptor antagonist (II 1 Ra) gene within synovial cells is regulated by an inflammation inducible promoter.
IN1682KON2014 2012-02-02 2013-01-23 IN2014KN01682A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20120000703 EP2623604B8 (en) 2012-02-02 2012-02-02 Adenoviral-based biological delivery and expression system for use in the treatment of osteoarthritis
PCT/IB2013/000198 WO2013114199A1 (en) 2012-02-02 2013-01-23 Adenoviral-based biological delivery and expression system for use in the treatment of osteoarthritis

Publications (1)

Publication Number Publication Date
IN2014KN01682A true IN2014KN01682A (en) 2015-10-23

Family

ID=47891791

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1682KON2014 IN2014KN01682A (en) 2012-02-02 2013-01-23

Country Status (12)

Country Link
US (4) US10301647B2 (en)
EP (1) EP2623604B8 (en)
JP (2) JP6340320B2 (en)
CN (1) CN104245941B (en)
AU (1) AU2013213873B2 (en)
CA (1) CA2861408C (en)
DK (1) DK2623604T3 (en)
EA (1) EA033004B1 (en)
ES (1) ES2534782T3 (en)
IN (1) IN2014KN01682A (en)
PL (1) PL2623604T3 (en)
WO (1) WO2013114199A1 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2948553T3 (en) 2013-01-25 2020-11-16 Baylor College Of Medicine A helper-dependent adenoviral gene therapy delivery and expression system
GB201410314D0 (en) * 2014-06-10 2014-07-23 Advanced Risc Mach Ltd Display controller
MX2017011037A (en) * 2015-03-02 2018-03-02 Synlogic Inc Bacteria engineered to treat diseases that benefit from reduced gut inflammation and/or tightened gut mucosal barrier.
RU2771490C2 (en) 2016-01-13 2022-05-05 Мериал, Инк. Recombinant aav vectors expressing osteoprotective genes, including has2 and lubricin, suitable in treatment of osteoarthritis and similar joint diseases in mammals
CN109843306A (en) 2016-08-19 2019-06-04 卡琳缪恩股份有限公司 Use the method and composition of self-complementary type recombinant adeno-associated virus treatment illness
US11529393B2 (en) 2016-10-10 2022-12-20 The Board Of Trustees Of The Leland Stanford Junior University Mesenchymal stem cells expressing anti-inflammatory cytokines and methods of use
AU2017371043B2 (en) * 2016-12-07 2022-12-15 University Of Florida Research Foundation, Incorporated IL-1Ra cDNAs
NZ758626A (en) 2017-04-21 2023-09-29 Baylor College Medicine Oncolytic virotherapy and immunotherapy
EP4031192A4 (en) * 2019-09-18 2023-10-25 Pacira Therapeutics, Inc. Effective dosages of an adenoviral-based biological delivery and expression system for use in the treatment of osteoarthritis in humans, and compositions comprising the same
JPWO2022234844A1 (en) * 2021-05-06 2022-11-10
AU2022335532A1 (en) * 2021-08-24 2024-03-07 Pacira Therapeutics, Inc. IL-1Ra GENE THERAPY FOR INTERVERTEBRAL DISC DEGENERATION

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5747072A (en) 1993-07-30 1998-05-05 University Of Michigan Adenoviral-mediated gene transfer to synovial cells in vivo
US20030091536A1 (en) 1999-09-07 2003-05-15 Colorado State University Research Foundation In vivo treatment of joint disease using interleukin-1
FR2806418B1 (en) * 2000-03-14 2004-07-16 Aventis Pharma Sa HYBRID INFLAMMATION INDUCIBLE PROMOTERS, VECTORS CONTAINING THEM, AND USES
WO2002083080A2 (en) 2001-04-17 2002-10-24 Genetix Pharmaceuticals, Inc. Method of treating arthritis using lentiviral vectors in gene therapy
JP4931919B2 (en) * 2005-06-21 2012-05-16 ゾーマ テクノロジー リミテッド IL-1β binding antibody and fragment thereof
US8298533B2 (en) * 2008-11-07 2012-10-30 Medimmune Limited Antibodies to IL-1R1
WO2010127275A1 (en) * 2009-05-01 2010-11-04 Oregon Health & Scince University Method of expanding human hepatocytes in vivo
SG2014014534A (en) * 2009-05-29 2014-07-30 Xoma Technology Ltd CARDIOVASCULAR RELATED USES OF IL-1ß ANTIBODIES AND BINDING FRAGMENTS THEREOF

Also Published As

Publication number Publication date
CN104245941B (en) 2016-12-07
JP2018075035A (en) 2018-05-17
US20190376080A1 (en) 2019-12-12
PL2623604T3 (en) 2015-07-31
CA2861408A1 (en) 2013-08-08
WO2013114199A8 (en) 2014-09-25
CA2861408C (en) 2021-10-26
US20220073948A1 (en) 2022-03-10
EP2623604B8 (en) 2015-04-22
WO2013114199A1 (en) 2013-08-08
DK2623604T3 (en) 2015-06-01
US20150031083A1 (en) 2015-01-29
JP2015506695A (en) 2015-03-05
EP2623604B1 (en) 2015-02-25
AU2013213873B2 (en) 2018-06-21
US20220348963A1 (en) 2022-11-03
JP6340320B2 (en) 2018-06-06
US10301647B2 (en) 2019-05-28
EA033004B1 (en) 2019-08-30
ES2534782T3 (en) 2015-04-28
CN104245941A (en) 2014-12-24
EP2623604A1 (en) 2013-08-07
AU2013213873A1 (en) 2014-09-25
EA201491457A1 (en) 2014-11-28

Similar Documents

Publication Publication Date Title
IN2014KN01682A (en)
PH12019500694A1 (en) Factor viii compositions and methods of making and using the same
Fayyad-Kazan et al. Downregulation of microRNA-24 and-181 parallels the upregulation of IFN-γ secreted by activated human CD4 lymphocytes
BR112018005620A2 (en) Stable and high level gene transfer method in lymphocytes
MX337040B (en) 4-1bb binding molecules.
NZ603813A (en) Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of histidyl-trna synthetases
BR112016028023A2 (en) COMPOSITIONS AND METHODS OF ADMINISTRATION OF TREATMENTS FOR LATENT VIRAL INFECTIONS
MX346923B (en) Genes and proteins for alkanoyl-coa synthesis.
MX362981B (en) Artificial nucleic acid molecules for improved protein or peptide expression.
EA201170506A1 (en) GENEVA THERAPY PORFOBILINGENDEZAMINAZOY
BRPI1013877A2 (en) IMPROVED AMINO ACID SEQUENCES AGAINST IL-6R AND POLYPEPTIDES COMPRISING THE SAME FOR THE TREATMENT OF IL-6R RELATED DISEASES AND DISORDERS
IN2014DN03061A (en)
MX2013003681A (en) Engineered nucleic acids and methods of use thereof.
IN2014DN03005A (en)
MX354516B (en) Vectors encoding rod-derived cone viability factor.
BRPI0607119A2 (en) nucleic acid construct, population of nucleic acid constructs, purified isolated chimeric promoter sequence, coated particles, dosage receptacle for a particle mediated delivery device, particle mediated delivery device, pharmaceutical composition, vaccine composition, and method in vitro to obtain expression in mammalian cells of an influenza polypeptide of interest
IN2014KN02823A (en)
MX2012005181A (en) Methods of propagating monkey adenoviral vectors.
IN2014CN04734A (en)
MX2013010392A (en) Npp1 fusion proteins.
NZ706884A (en) Fc gamma receptor iib variants
EP4200406A1 (en) Modified lymphocytes
Peröbner et al. LRP6 mediates Wnt/β-catenin signaling and regulates adipogenic differentiation in human mesenchymal stem cells
NZ709120A (en) Beta-hexosyl-transferases and uses thereof
Locatelli et al. Efficient plasmid-mediated gene transfection of ovine bone marrow mesenchymal stromal cells